| Literature DB >> 32202512 |
Xin Zhou1, Chenxi He2, Jiangong Ren1, Congxin Dai1,3, Sharon R Stevens4, Qianghu Wang5, Daniel Zamler6,7, Takashi Shingu1, Liang Yuan1,8, Chythra R Chandregowda1, Yunfei Wang9, Visweswaran Ravikumar10, Arvind Uk Rao10,11,12, Feng Zhou13, Hongwu Zheng14, Matthew N Rasband4, Yiwen Chen15, Fei Lan2, Amy B Heimberger16, Benjamin M Segal17,18, Jian Hu1,7.
Abstract
Lipid-rich myelin forms electrically insulating, axon-wrapping multilayers that are essential for neural function, and mature myelin is traditionally considered metabolically inert. Surprisingly, we discovered that mature myelin lipids undergo rapid turnover, and quaking (Qki) is a major regulator of myelin lipid homeostasis. Oligodendrocyte-specific Qki depletion, without affecting oligodendrocyte survival, resulted in rapid demyelination, within 1 week, and gradually neurological deficits in adult mice. Myelin lipids, especially the monounsaturated fatty acids and very-long-chain fatty acids, were dramatically reduced by Qki depletion, whereas the major myelin proteins remained intact, and the demyelinating phenotypes of Qki-depleted mice were alleviated by a high-fat diet. Mechanistically, Qki serves as a coactivator of the PPARβ-RXRα complex, which controls the transcription of lipid-metabolism genes, particularly those involved in fatty acid desaturation and elongation. Treatment of Qki-depleted mice with PPARβ/RXR agonists significantly alleviated neurological disability and extended survival durations. Furthermore, a subset of lesions from patients with primary progressive multiple sclerosis were characterized by preferential reductions in myelin lipid contents, activities of various lipid metabolism pathways, and expression level of QKI-5 in human oligodendrocytes. Together, our results demonstrate that continuous lipid synthesis is indispensable for mature myelin maintenance and highlight an underappreciated role of lipid metabolism in demyelinating diseases.Entities:
Keywords: Demyelinating disorders; Metabolism; Multiple sclerosis; Neuroscience
Mesh:
Substances:
Year: 2020 PMID: 32202512 PMCID: PMC7191000 DOI: 10.1172/JCI131800
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808